NYSE American - Nasdaq Real Time Price USD

Asensus Surgical, Inc. (ASXC)

0.3320 +0.0972 (+41.40%)
At close: June 7 at 4:00 PM EDT
0.3310 -0.00 (-0.30%)
After hours: June 7 at 7:56 PM EDT
Loading Chart for ASXC
DELL
  • Previous Close 0.2348
  • Open 0.3340
  • Bid 0.3300 x 36900
  • Ask 0.3311 x 2200
  • Day's Range 0.3270 - 0.3389
  • 52 Week Range 0.2000 - 0.6500
  • Volume 36,021,022
  • Avg. Volume 2,144,747
  • Market Cap (intraday) 90.414M
  • Beta (5Y Monthly) 1.29
  • PE Ratio (TTM) --
  • EPS (TTM) -0.3000
  • Earnings Date Aug 8, 2024 - Aug 12, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 0.35

Asensus Surgical, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery (MIS) in the United States, Europe, the Middle East, Africa, and Asia. It digitizes the interface between the surgeon and the patient to perform performance-guided surgery for surgeons to deliver outcomes to patients. The company's products include Senhance System, a multi-port robotic surgery system that allows up to four arms to control robotic instruments and a camera for laparoscopic procedures; instruments and other products, including 3mm diameter instruments, 3mm and 5mm hooks, and articulating instruments; and Senhance ultrasonic system, an advanced energy device to deliver controlled energy to ligate and divide tissue. The company was formerly known as TransEnterix, Inc. and changed its name to Asensus Surgical, Inc. in February 2021. Asensus Surgical, Inc. is headquartered in Durham, North Carolina.

www.asensus.com

207

Full Time Employees

December 31

Fiscal Year Ends

Recent News: ASXC

Performance Overview: ASXC

Trailing total returns as of 6/7/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

ASXC
3.75%
S&P 500
12.10%

1-Year Return

ASXC
40.71%
S&P 500
24.82%

3-Year Return

ASXC
88.90%
S&P 500
26.41%

5-Year Return

ASXC
98.02%
S&P 500
88.04%

Compare To: ASXC

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: ASXC

Valuation Measures

Annual
As of 6/7/2024
  • Market Cap

    90.41M

  • Enterprise Value

    87.88M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    9.80

  • Price/Book (mrq)

    6.94

  • Enterprise Value/Revenue

    10.07

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -67.39%

  • Return on Equity (ttm)

    -169.75%

  • Revenue (ttm)

    8.72M

  • Net Income Avi to Common (ttm)

    -78.71M

  • Diluted EPS (ttm)

    -0.3000

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    7.99M

  • Total Debt/Equity (mrq)

    41.89%

  • Levered Free Cash Flow (ttm)

    -23.27M

Research Analysis: ASXC

Company Insights: ASXC

Research Reports: ASXC

People Also Watch